Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Michael Y. Choi; George F. Widhopf; Christina C.N. Wu; Bing Cui; Fitzgerald Lao; Anil Sadarangani; Joy Cavagnaro; Charles Prussak; Dennis A. Carson; Catriona Jamieson; Thomas J. Kipps

doi:10.1016/j.clml.2015.02.010

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Michael Y. Choi, George F. Widhopf, Christina C.N. Wu, Bing Cui, Fitzgerald Lao, Anil Sadarangani, Joy Cavagnaro, Charles Prussak, Dennis A. Carson, Catriona Jamieson, Thomas J. Kipps

Research output: Contribution to journal › Review article › peer-review

84 Scopus citations

Abstract

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.

Original language	English
Article number	549
Pages (from-to)	S167-S169
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	15
Issue number	S
DOIs	https://doi.org/10.1016/j.clml.2015.02.010
State	Published - 1 Jun 2015
Externally published	Yes

Bibliographical note

Funding Information:
Conflicts of interest: none. Financial support for the conduct of the research was provided by the Leukemia Lymphoma Society (SCOR 7005-14), the National Institutes of Health grant for the CLL Research Consortium (P01-CA081534), and the California Institute of Regenerative Medicine (DR3-06924)

Publisher Copyright:
© 2015 The Authors.

Keywords

AKT
CLL
Cirmtuzumab
Wnt receptor
cancer stem cell

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2015.02.010

Cite this

Choi, M. Y., Widhopf, G. F., Wu, C. C. N., Cui, B., Lao, F., Sadarangani, A., Cavagnaro, J., Prussak, C., Carson, D. A., Jamieson, C., & Kipps, T. J. (2015). Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clinical Lymphoma, Myeloma and Leukemia, 15(S), S167-S169. Article 549. https://doi.org/10.1016/j.clml.2015.02.010

@article{45a4094472ed43208f30f29f4e94f849,

title = "Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1",

abstract = "Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.",

keywords = "AKT, CLL, Cirmtuzumab, Wnt receptor, cancer stem cell",

author = "Choi, {Michael Y.} and Widhopf, {George F.} and Wu, {Christina C.N.} and Bing Cui and Fitzgerald Lao and Anil Sadarangani and Joy Cavagnaro and Charles Prussak and Carson, {Dennis A.} and Catriona Jamieson and Kipps, {Thomas J.}",

note = "Funding Information: Conflicts of interest: none. Financial support for the conduct of the research was provided by the Leukemia Lymphoma Society (SCOR 7005-14), the National Institutes of Health grant for the CLL Research Consortium (P01-CA081534), and the California Institute of Regenerative Medicine (DR3-06924) Publisher Copyright: {\textcopyright} 2015 The Authors.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.clml.2015.02.010",

language = "English",

volume = "15",

pages = "S167--S169",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "S",

}

TY - JOUR

T1 - Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

AU - Choi, Michael Y.

AU - Widhopf, George F.

AU - Wu, Christina C.N.

AU - Cui, Bing

AU - Lao, Fitzgerald

AU - Sadarangani, Anil

AU - Cavagnaro, Joy

AU - Prussak, Charles

AU - Carson, Dennis A.

AU - Jamieson, Catriona

AU - Kipps, Thomas J.

N1 - Funding Information: Conflicts of interest: none. Financial support for the conduct of the research was provided by the Leukemia Lymphoma Society (SCOR 7005-14), the National Institutes of Health grant for the CLL Research Consortium (P01-CA081534), and the California Institute of Regenerative Medicine (DR3-06924) Publisher Copyright: © 2015 The Authors.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.

AB - Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.

KW - AKT

KW - CLL

KW - Cirmtuzumab

KW - Wnt receptor

KW - cancer stem cell

UR - http://www.scopus.com/inward/record.url?scp=84939622740&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2015.02.010

DO - 10.1016/j.clml.2015.02.010

M3 - Review article

C2 - 26297272

AN - SCOPUS:84939622740

SN - 2152-2650

VL - 15

SP - S167-S169

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - S

M1 - 549

ER -

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this